Randomized, multicenter study for adjuvant treatment of stage III malignant melanoma: intermittent, high-dose intravenous interferon alpha-2b versus standard high-dose interferon alpha-2b therapy
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interferon alpha-2b; Interferon alpha-2b
- Indications Malignant melanoma
- Focus Therapeutic Use
- 07 Jun 2012 Status changed from recruiting to completed.
- 29 May 2009 Planned number of patients changed from 600 to 631, as reported reported in an abstract available on-line only in association with ASCO 2009.
- 29 May 2009 Interim quality-of-life data from 377 of the planned 631 patients were reported in an abstract available on-line only in association with ASCO 2009.